



- (51) **International Patent Classification:**
A61K 47/68 (2017.01) *C12P 13/14* (2006.01)
- (21) **International Application Number:**
PCT/EP2023/054469
- (22) **International Filing Date:**
22 February 2023 (22.02.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
22158087.1 22 February 2022 (22.02.2022) EP
22182782.7 04 July 2022 (04.07.2022) EP
- (71) **Applicant:** ADC THERAPEUTICS SA [CH/CH];
Biopôle, Route de la Corniche 3B, 1066 Epalinges (CH).
- (72) **Inventors:** BIRD, Matthew; c/o ADC Therapeutics (UK)
Ltd., I-HUB, Imperial College White City Campus, 84
Wood Lane, London Greater London W12 0BZ (GB). VAN
BERKEL, Patricius Hendrikus Cornelis; c/o ADC Ther-
apeutics (UK) Ltd., I-HUB, Imperial College White City
Campus, 84 Wood Lane, London Greater London W12 0BZ
(GB).
- (74) **Agent:** FINNIE, Nicholas; ADC Therapeutics (UK) Ltd.,
I-HUB, Imperial College White City Campus, 84 Wood
Lane, London Greater London W12 0BZ (GB).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

- (54) **Title:** CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN

**FIG. 1**

- (57) **Abstract:** Described herein are methods for conjugating moieties of interest, such as pharmaceutically active molecules, to targeting molecules such as antibodies using transglutaminase-based processes.

